Guided Therapeutics Inc. (OTCMKTS:GTHP) Stock Short Interest Report for September

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 3,727 shares, a decrease of 45.4% from the September 15th total of 6,822 shares. Based on an average daily volume of 127,857 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Guided Therapeutics Price Performance

Guided Therapeutics stock traded up $0.01 during midday trading on Thursday, reaching $0.19. The company had a trading volume of 601 shares, compared to its average volume of 20,757. The company has a market capitalization of $18.66 million, a P/E ratio of -4.75 and a beta of 0.70. Guided Therapeutics has a 12-month low of $0.15 and a 12-month high of $0.54. The firm’s fifty day simple moving average is $0.24 and its 200-day simple moving average is $0.24.

Guided Therapeutics (OTCMKTS:GTHP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Guided Therapeutics

Guided Therapeutics, Inc is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets.